**

Pharmaceutical exports from India, a global leader in generic drug manufacturing, are facing a significant threat due to the newly implemented Certificate of Pharmaceutical Products (COPP) mandate, according to the Pharmaceuticals Export Promotion Council of India (Pharmexcil). The organization has issued an urgent call for a review of the stringent regulations, warning of potential disruptions to the vital pharmaceutical supply chain and significant economic repercussions for India.

COPP Mandate: A Major Hurdle for Indian Pharma Exports

The COPP mandate, implemented by various importing countries to ensure the quality and authenticity of pharmaceutical products, requires manufacturers to obtain certificates verifying compliance with Good Manufacturing Practices (GMP) and other regulatory standards. While intended to safeguard public health, Pharmexcil argues that the current implementation poses significant challenges for Indian pharmaceutical exporters.

Increased Compliance Costs and Delays

One of the primary concerns highlighted by Pharmexcil is the substantial increase in compliance costs and bureaucratic delays associated with the COPP process. Many small and medium-sized enterprises (SMEs), which form a crucial part of India's pharmaceutical export landscape, lack the resources to navigate the complex regulatory maze effectively. This results in:

• Higher certification fees: Obtaining COPP certificates involves significant expenses, potentially impacting the competitiveness of Indian pharmaceutical products in the global market.
• Time-consuming processes: The lengthy application and verification processes associated with COPP applications are leading to substantial delays in export shipments, causing disruptions to supply chains and jeopardizing contracts.
• Increased paperwork and documentation: The increased administrative burden associated with COPP compliance places a heavy strain on resources, diverting attention and manpower away from core production activities.
• Risk of rejection: Even with meticulous compliance, there is a risk of certificate rejection due to minor discrepancies or inconsistencies in documentation, further compounding the delays and costs.

These challenges are particularly acute for exporters of essential medicines and generics, which often operate on tight margins. The added costs associated with COPP compliance could render many products uncompetitive, pushing buyers toward alternatives from other manufacturing hubs.

Impact on Indian Pharmaceutical Industry and Global Supply Chains

The potential consequences of the COPP mandate are far-reaching, impacting not only Indian pharmaceutical companies but also global healthcare systems reliant on affordable and accessible medicines. The disruption of Indian pharmaceutical exports could:

• Increase drug prices globally: Reduced supply from India could lead to higher prices for essential medicines, particularly in developing countries heavily dependent on Indian generics.
• Create shortages of vital medications: Delays in export shipments could cause critical shortages of life-saving drugs in various regions across the globe.
• Damage India's reputation as a reliable pharmaceutical supplier: The current challenges with COPP compliance could negatively impact India’s standing as a trusted source of high-quality, affordable medicines.

Urgent Need for a Streamlined Process

Pharmexcil has urged the Indian government to intervene and work with importing countries to create a more streamlined and efficient COPP certification process. The organization recommends:

• Harmonizing regulatory standards: Closer collaboration with international regulatory agencies to align standards and reduce inconsistencies in compliance requirements.
• Facilitating digitalization: Implementation of a digital platform for COPP application and processing to reduce paperwork and streamline the process.
• Providing support to SMEs: Offering financial and technical assistance to small and medium-sized enterprises to help them navigate the COPP compliance requirements.
• Establishing a dedicated help desk: Creating a centralized resource to assist exporters with COPP-related queries and address any challenges faced during the application process.

Seeking Government Intervention and Industry Collaboration

Pharmexcil’s appeal underscores the urgency of addressing the issues surrounding the COPP mandate. The organization is calling for a multi-pronged approach involving:

• Government advocacy: Active engagement with foreign governments to emphasize the importance of a streamlined COPP process and its impact on global healthcare access.
• Industry collaboration: Sharing best practices and experiences among Indian pharmaceutical companies to develop effective strategies for COPP compliance.
• Transparency and communication: Improving communication and information-sharing between regulatory agencies and pharmaceutical exporters to ensure clarity and efficiency.

The COPP mandate presents a substantial challenge to India's pharmaceutical industry and its crucial role in providing affordable medicines globally. Addressing the concerns raised by Pharmexcil through collaborative action between the government, regulatory bodies, and the pharmaceutical industry is vital to ensuring the continued accessibility of essential medications worldwide. The future of Indian pharmaceutical exports and global drug supply chains hangs in the balance. A timely and effective response is crucial to mitigate potential disruptions and safeguard public health.